A Cleveland Clinic trial studies a 12-week web-based coaching program for those with psoriatic disease.Read More
Intravenous golimumab is both safe and effective over a one-year treatment period for patients with psoriatic arthritis. Rheumatologist Elaine Husnie, MD, MPH, discusses the findings.
Research reveals a defect in myosin binding to TNFR2-M196R causes TNF-independent proinflammatory activity. The ability to genotype this polymorphism should help to predict inadequate responders to anti-TNF therapies early on, and allowing a personalized approach to the treatment of rheumatoid and psoriatic diseases.
For patients, visible symptoms of uveitis correlate with perceptions of worse physical health, according to a recent study. Ophthalmologist Sunil Srivastava, MD, and rheumatologists Rula Hajj-Ali, Joshua Hedrick, MD, explain the relationship between patient reported outcomes measures and disease activity in inflammatory eye disease.
Preclinical models suggest that specific blockade of TNFR2 may significantly reduce inflammation and ameliorate signs of psoriatic diseases, while maintaining normal immune response in the host, including the ability to combat infection and cancer. In this article, M. Elaine Husni, MD, MPH, highlights her latest research and discusses her plans to use her new R01 grant to continue her translational work.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
A new study of long-term outcomes in primary angiitis of the central nervous system suggests that mortality is significant, but long-term disability is mild. Dr. Rula Hajj-Ali describes her research efforts and the need for prognostic markers.
A patient-reported outcomes system takes us one step closer to understanding MCID in immune-mediated diseases.
With the MyRheum system, Cleveland Clinic collects patient-reported health measures at each rheumatology clinic visit. Here’s how it works and how it’s changing clinical care.
One of rheumatology’s most common dilemmas is distinguishing the cause of fevers in patients with rheumatic diseases, such as lupus. The ratio of elevated sedimentation rate (ESR) to C-reactive protein (CRP) may help.
Rheumatologists have long known that lowering plasma urate in patients with gout increases flares, but we haven’t known exactly why.
The ORAL Strategy randomized controlled trial evaluates the effect of LZV on HZ rates in rheumatoid arthritis patients who respond inadequately to methotrexate and are treated with biologics.